<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986596</url>
  </required_header>
  <id_info>
    <org_study_id>2450</org_study_id>
    <secondary_id>7528</secondary_id>
    <nct_id>NCT00986596</nct_id>
  </id_info>
  <brief_title>A Pilot Study of the Impact of Vitamin D3 on Muscle Performance in Elderly Women</brief_title>
  <official_title>A Pilot Study of the Impact of Vitamin D3 on Muscle Performance in Elderly Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the effect of vitamin D on muscle tissue and&#xD;
      physical performance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have recently observed that among healthy women age 65 and older who&#xD;
      participated in a placebo-controlled vitamin D and calcium intervention trial, those treated&#xD;
      with supplements had a lower risk of falling than those in the placebo group. Vitamin D&#xD;
      receptors (VDRs) are present in muscle tissue and are thought to mediate the favorable&#xD;
      effects of vitamin D on muscle performance. Vitamin D insufficiency is common particularly in&#xD;
      the elderly and supplementation with a relatively high dose of vitamin D may be a useful&#xD;
      approach for improving muscle performance and potentially lowering the risk of falling in&#xD;
      sedentary older women and other high-risk populations.&#xD;
&#xD;
      The investigators will aim to study women, age 65 and older, with 25(OH)D levels below 60&#xD;
      nmol/l in a double-blind, 4-month randomized controlled pilot study. Eligible subjects will&#xD;
      be randomized to treatment with 4000 IU per day of vitamin D3 or placebo. Blood and 24 hour&#xD;
      urine will be measured at the beginning and end of the study as outlined in the intervention&#xD;
      and measurement schedule below. In addition, a safety random spot urine will be analyzed for&#xD;
      calcium and creatinine on day 30. Muscle performance measures will be measured and muscle&#xD;
      biopsies will be performed at the beginning and end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define and compare changes in size and number of type II muscle fibers in response to 4 months of treatment with 4000 IU of vitamin D3 per day or placebo in older women with low-normal 25(OH)D levels.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define and compare vitamin D signaling in muscle biopsy specimens taken before and after the treatment.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define and compare changes in clinical measures of muscle performance before and after treatment</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Define and compare levels of bone turnover before and after treatment</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Falls</condition>
  <arm_group>
    <arm_group_label>vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vitamin D3 capsule 4000 IU p.o. daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>4000 IU once daily by mouth for 4 months</description>
    <arm_group_label>vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 65 and older&#xD;
&#xD;
          -  25 (OH)D levels &gt;22.5 nmol/l or &lt;60 nmol/l&#xD;
&#xD;
          -  Women must have a composite physical performance score of â‰¤ 9 out of a possible score&#xD;
             of 12.&#xD;
&#xD;
          -  Subjects must agree not to change their usual level of physical activity or change the&#xD;
             amount of calcium and vitamin D supplement they use for the duration of the study.&#xD;
&#xD;
          -  If they are taking calcium supplements, they must agree to take the supplement any&#xD;
             time after lunch.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General:&#xD;
&#xD;
               1. Total calcium intake &gt;1000mg daily on the prescreening questionnaire.&#xD;
&#xD;
               2. More than 400 IU daily of supplemental vitamin D on the prescreening&#xD;
                  questionnaire.&#xD;
&#xD;
               3. A screening 25(OH)D level &gt; 60 nmol/ L.&#xD;
&#xD;
               4. Screening 24-hour urine calcium &gt; 275 mg.&#xD;
&#xD;
               5. An abnormal serum calcium.&#xD;
&#xD;
               6. Travel to latitude &lt;35 degrees N within 2 months of the time of enrollment; plans&#xD;
                  to travel to latitude &lt;35 degrees N during the 4-month study, with the likelihood&#xD;
                  of tanning (e.g. appreciable sun exposure without sun screen).&#xD;
&#xD;
               7. Greater than 2 drinks of alcohol a day.&#xD;
&#xD;
          -  Medications:&#xD;
&#xD;
               1. Bone active drugs such as bisphosphonates, estrogen, calcitonin, teriparatide&#xD;
&#xD;
               2. Diuretics&#xD;
&#xD;
               3. Oral glucocorticoids in the last month&#xD;
&#xD;
               4. Phosphates in the last week&#xD;
&#xD;
               5. Lithium&#xD;
&#xD;
               6. Cod liver oil&#xD;
&#xD;
               7. Total parenteral nutrition&#xD;
&#xD;
               8. Calcium containing antacids&#xD;
&#xD;
               9. Coumadin or other prescribed anticoagulants&#xD;
&#xD;
          -  Diseases:&#xD;
&#xD;
               1. Active thyroid disease - unstable levothyroxine dose&#xD;
&#xD;
               2. Parathyroid disease&#xD;
&#xD;
               3. Sarcoidosis&#xD;
&#xD;
               4. Fracture of the foot, leg, or hip in the last year&#xD;
&#xD;
               5. Renal stone &lt; 5 years&#xD;
&#xD;
               6. Alkaline phosphatase &gt; 10% above the upper limit of normal&#xD;
&#xD;
               7. Pancreatitis&#xD;
&#xD;
               8. Active malignancy (other than basal cell cancer of the skin) or cancer therapy in&#xD;
                  the last year&#xD;
&#xD;
               9. Uncontrolled arrhythmia in last year&#xD;
&#xD;
              10. Malabsorption&#xD;
&#xD;
              11. Use of a walker or wheelchair (3-post cane okay)&#xD;
&#xD;
              12. Nasal oxygen use&#xD;
&#xD;
              13. Must have a basic mobility level of walking 4 meters&#xD;
&#xD;
              14. Hemiplegia&#xD;
&#xD;
              15. Tuberculosis&#xD;
&#xD;
              16. Type 1 Diabetes mellitus or unstable type 2 diabetes mellitus (fasting blood&#xD;
                  glucose &gt;130 mg/dL)&#xD;
&#xD;
              17. Other abnormality in screening labs, at the discretion of the study physician&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bess Dawson-Hughes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Ceglia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tufts University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>January 6, 2012</last_update_submitted>
  <last_update_submitted_qc>January 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Bess Dawson-Hughes</investigator_full_name>
    <investigator_title>Director, Bone Metabolism Laboratory</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>skeletal muscle</keyword>
  <keyword>vitamin D receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

